IPO registrations (S-1, F-1) · Registrants
ACHILLION PHARMACEUTICALS INC
- SEC CIK
- 1070336 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2006-03-31, last 2009-08-14; 2 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2006-10-26; declared effective 2006-10-25; withdrawal requested 2006-10-18
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 300 GEORGE STREET, New Haven, CT 06511
- EDGAR entity type
- operating
- Insiders and CEO pay
- ACHILLION PHARMACEUTICALS INC on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2006-10-25)
- Final price
- $11.50 per share, below the range (424B4 filed 2006-10-26, an initial public offering)
- Shares sold
- 4,500,000
- Gross proceeds
- $51,750,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ACHN
- Lead underwriters
- Cowen; CIBC World Markets; JMP Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ACHILLION PHARMACEUTICALS, INC. Fuzzy (name and state)
- Federal award recipient: ACHILLION PHARMACEUTICALS, INC. Fuzzy (name and state)
- SEC filer: ACHILLION PHARMACEUTICALS INC EXACT (CIK (EXACT))
- Person page: James M Garvey Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,TenPercentOwner))
Filings 20
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2006-03-31 | S-1 | S-1 (registration) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-070902 ↗ |
| 2006-05-17 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-114379 ↗ |
| 2006-06-06 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-124479 ↗ |
| 2006-09-01 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-183778 ↗ |
| 2006-09-22 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-194948 ↗ |
| 2006-10-02 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-200497 ↗ |
| 2006-10-10 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-204889 ↗ |
| 2006-10-18 | RW | RW (withdrawal request) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-210019 ↗ |
| 2006-10-20 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-211314 ↗ |
| 2006-10-25 | S-1/A | S-1/A (amendment) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-214521 ↗ |
| 2006-10-25 | EFFECT | EFFECT (declared effective) | ACHILLION PHARMACEUTICALS INC | 9999999995-06-002034 ↗ |
| 2006-10-26 | 424B4 | 424B4 (final prospectus) | ACHILLION PHARMACEUTICALS INC | 0001193125-06-215579 ↗ |
| 2008-04-11 | RW | RW (withdrawal request) | ACHILLION PHARMACEUTICALS INC | 0001193125-08-079933 ↗ |
| 2008-10-30 | EFFECT | EFFECT (declared effective) | ACHILLION PHARMACEUTICALS INC | 9999999995-08-003245 ↗ |
| 2009-08-14 | S-1 | S-1 (registration) | ACHILLION PHARMACEUTICALS INC | 0001193125-09-176126 ↗ |
| 2009-09-21 | EFFECT | EFFECT (declared effective) | ACHILLION PHARMACEUTICALS INC | 9999999995-09-002616 ↗ |
| 2009-10-16 | EFFECT | EFFECT (declared effective) | ACHILLION PHARMACEUTICALS INC | 9999999995-09-002882 ↗ |
| 2010-05-26 | EFFECT | EFFECT (declared effective) | ACHILLION PHARMACEUTICALS INC | 9999999995-10-001619 ↗ |
| 2010-09-30 | EFFECT | EFFECT (declared effective) | ACHILLION PHARMACEUTICALS INC | 9999999995-10-002837 ↗ |
| 2011-04-25 | EFFECT | EFFECT (declared effective) | ACHILLION PHARMACEUTICALS INC | 9999999995-11-001154 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2006-10-25 | S-1/A | registration statement | $14.00–$16.00 | 4,500,000 | - | Nasdaq ACHN | 3 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 3 | document ↗ | |
| 2006-10-26 | 424B4 | final prospectus | $11.50 | 4,500,000 | $51,750,000 | Nasdaq ACHN | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ADVENT HEALTHCARE & LIFE SCIENCES II KG | Other | 2 | 2006 | ||
| ADVENT HEALTHCARE & LIFE SCIENCES II LP | Other | 2 | 2006 | ||
| ADVENT INTERNATIONAL CORP/MA | Other | 2 | 2006 | ||
| ADVENT INTERNATIONAL LIMITED PARTNERSHIP | Other | 2 | 2006 | ||
| ADVENT PARTNERS HLS II LIMITED PARTNERSHIP | Other | 2 | 2006 | ||
| ADVENT PARTNERS LIMITED PARTNERSHIP | Other | 2 | 2006 | ||
| ATLAS VENTURE ASSOCIATES V LP | TenPercentOwner | 2 | 2006 | ||
| ATLAS VENTURE ENTREPRENEURS FUND V LP | TenPercentOwner | 2 | 2006 | ||
| ATLAS VENTURE FUND V LP | TenPercentOwner | 2 | 2006 | ||
| ATLAS VENTURE PARALLEL FUND V-A C V | TenPercentOwner | 2 | 2006 | ||
| Deshpande Milind | Director,Officer; Officer | Chief Executive Officer; EVP and CSO; President and CEO; President and CSO; President of R&D and CSO; Pres R&D and CSO; SVP and Chief Scientific Ofc.; SVP and CSO | 24 | 2006–2018 | |
| Fenton Mary Kay | Officer | Chief Financial Officer; EVP and CFO; SVP and CFO; Vice President and CFO | 23 | 2006–2018 | |
| FISHERMAN JASON S | Director | 29 | 2006–2020 | ||
| FORMELA JEAN FRANCOIS | Director,TenPercentOwner | 3 | 2006–2007 | ||
| GARVEY JAMES M | Director,TenPercentOwner | 3 | 2006–2007 | person page Fuzzy | |
| GILEAD SCIENCES INC | TenPercentOwner | 2 | 2006 | ||
| GREY MICHAEL G | Director | 6 | 2006–2009 | ||
| KISHBAUCH MICHAEL D | Director; Director,Officer | CEO and President | 22 | 2006–2020 | |
| Pottage John C Jr | Officer | SVP and Chief Medical Officer | 2 | 2006 | |
| RYSER STEFAN | Director | 2 | 2006 | ||
| Scheer David | Director | 19 | 2006–2020 | ||
| SCHRODER VENTURE MANAGERS LTD | TenPercentOwner | 2 | 2006 | ||
| SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES FUND II LP1 | TenPercentOwner | 2 | 2006 | ||
| Schroder Ventures International Life Sciences Fund II L.P.2 | TenPercentOwner | 2 | 2006 | ||
| Schroder Ventures International Life Sciences Fund II L.P.3 | TenPercentOwner | 2 | 2006 | ||
| Schroder Ventures International Life Sciences Fund II Strategic Partners L.P. | TenPercentOwner | 2 | 2006 | ||
| SCHRODER VENTURES MANAGERS INC | TenPercentOwner | 2 | 2006 | ||
| Shah Gautam | Officer | EVP and Chief Compliance Ofc.; SVP and Chief Compliance Ofc. | 29 | 2006–2014 | |
| SITCO Nominees Ltd. VC 01903 as Nominee of Schroder Ventures International Life Sciences Fund II Group Co-Investment Scheme | TenPercentOwner | 2 | 2006 | ||
| SV (Nominees) LTD as Nominee of Schroder Ventures Investments LTD | TenPercentOwner | 2 | 2006 | ||
| WHITE CHRISTOPHER A | Director | 2 | 2006 | ||
| VAN NOSTRAND ROBERT L | Director | 18 | 2007–2020 | ||
| WRIGHT DAVID P | Director | 12 | 2007–2012 | ||
| Olek Elizabeth A | Officer | Senior Vice President and CMO; SVP and CMO; Vice President and CMO | 9 | 2007–2012 | |
| FRASHIER GARY E | Director | 19 | 2008–2018 | ||
| Clarus Lifesciences II, L.P. | TenPercentOwner | 10 | 2008–2012 | ||
| Clarus Ventures II GP, L.P. | TenPercentOwner | 10 | 2008–2012 | ||
| Clarus Ventures II, LLC | TenPercentOwner | 10 | 2008–2012 | ||
| GALAKATOS NICHOLAS | TenPercentOwner | 10 | 2008–2012 | ||
| HENNER DENNIS | TenPercentOwner | 10 | 2008–2012 | ||
| Leiden Jeffrey | TenPercentOwner | 8 | 2008–2010 | ||
| LIPTAK ROBERT | TenPercentOwner | 10 | 2008–2012 | ||
| Simon Nicholas | Director; Director,TenPercentOwner; TenPercentOwner | 15 | 2008–2012 | ||
| STEINMETZ MICHAEL | TenPercentOwner | 10 | 2008–2012 | ||
| WHEELER KURT | TenPercentOwner | 10 | 2008–2012 | ||
| Moorin Jay | TenPercentOwner | 2 | 2008–2009 | ||
| ProQuest Associates IV LLC | TenPercentOwner | 2 | 2008–2009 | ||
| ProQuest Investments IV, L.P. | TenPercentOwner | 2 | 2008–2009 | ||
| SCHREIBER ALAIN | TenPercentOwner | 2 | 2008–2009 | ||
| INVESTOR AB | TenPercentOwner | 8 | 2008–2010 | ||
| INVESTOR GROWTH CAPITAL LTD | TenPercentOwner | 6 | 2008–2010 | ||
| Liotta Dennis | Director | 15 | 2008–2014 | ||
| Truitt Joseph | Director,Officer; Officer | Chief Commercial Officer; Chief Executive Officer; EVP, Chief Commercial Officer; SVP, Chief Commercial Officer; VP, Chief Commercial Officer | 20 | 2009–2020 | |
| BLAIR JAMES C | TenPercentOwner | 4 | 2010–2013 | ||
| Domain Partners VIII, L.P. | TenPercentOwner | 3 | 2010–2013 | ||
| DOVEY BRIAN H | TenPercentOwner | 4 | 2010–2013 | ||
| DP VIII Associates, L.P. | TenPercentOwner | 1 | 2010 | ||
| Halak Brian K | TenPercentOwner | 4 | 2010–2013 | ||
| SCHOEMAKER KATHLEEN K | TenPercentOwner | 4 | 2010–2013 | ||
| TREU JESSE I | TenPercentOwner | 4 | 2010–2013 | ||
| VITULLO NICOLE | Director; Director,TenPercentOwner; TenPercentOwner | 22 | 2010–2020 | ||
| Quaker BioVentures II LP | TenPercentOwner | 4 | 2010–2011 | ||
| DOMAIN ASSOCIATES | TenPercentOwner | 1 | 2010 | ||
| Kamdar Kim P. | TenPercentOwner | 1 | 2012 | ||
| Graves Kurt | Director | 10 | 2012–2020 | ||
| QVT Associates GP LLC | TenPercentOwner | 14 | 2013–2014 | ||
| Apelian David | Officer | Chief Medical Officer; EVP and Chief Medical Officer; EVP and CMO | 8 | 2013–2017 | |
| QVT Fund V LP | TenPercentOwner | 6 | 2013 | ||
| Kolchinsky Peter | Other; TenPercentOwner; TenPercentOwnerOther | 19 | 2013–2015 | ||
| RA Capital Healthcare Fund LP | Other; TenPercentOwner; TenPercentOwnerOther | 19 | 2013–2015 | ||
| RA CAPITAL MANAGEMENT, LLC | Other; TenPercentOwner; TenPercentOwnerOther | 21 | 2013–2015 | ||
| JOHNSON & JOHNSON | TenPercentOwner | 2 | 2015–2017 | ||
| Johnson & Johnson Innovation - JJDC, Inc. | TenPercentOwner | 2 | 2015–2017 | ||
| Verwiel Frank | Director | 7 | 2015–2020 | ||
| Barrish Joel C | Officer | Chief Scientific Officer | 5 | 2016–2017 | |
| MANNING MARTHA E | Officer | EVP, General Counsel; General Counsel | 7 | 2016–2020 | |
| Gibney Anthony S | Officer | Chief Business Officer; EVP, Chief Business Officer | 4 | 2018–2020 | |
| Zelenkofske Steven | Officer | Chief Medical Officer; EVP, Chief Medical Officer | 4 | 2018–2020 | |
| Firuta Paul E | Officer | Chief Operating Officer; EVP, Chief Commercial Officer | 4 | 2018–2020 | |
| Lantz Keri | Officer | See Remarks | 2 | 2019 | |
| Di Donato Brian | Officer | Chief Financial Officer; SVP, Chief Financial Officer | 4 | 2019–2020 | |
| G1 EXECUTION SERVICES, LLC | TenPercentOwner | 2 | 2020 | ||
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | TenPercentOwner | 2 | 2020 | ||
| SUSQUEHANNA SECURITIES, LLC | TenPercentOwner | 2 | 2020 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ACHILLION PHARMACEUTICALS, INC. | CT | State business registries | name and state |
| Plan sponsor | ACHILLION PHARMACEUTICALS, INC. | CT | Form 5500 (employee benefit plans) | name and state |
| Federal award recipient | ACHILLION PHARMACEUTICALS, INC. | CT | Federal spending (USAspending) | name and state |
| Patent assignee | Achillion Pharmaceuticals, Inc. | CT | Patents (USPTO) | name and state |
| SEC filer | ACHILLION PHARMACEUTICALS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Achillion Pharmaceuticals, Inc. | CT | Trademarks (USPTO) | name and state |
| Person page | James M Garvey | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CT first:
- CHIREX INC CT
- Rib-X Pharmaceuticals, Inc. CT
- Oracle Healthcare Acquisition Corp. CT
- NANOVIRICIDES, INC. CT
- KOLLTAN PHARMACEUTICALS INC CT
- Trevi Therapeutics, Inc. CT
- Yarrow Bioscience, Inc. CT
- Loxo Oncology, Inc. CT
- ARVINAS, INC. CT
- Biohaven Pharmaceutical Holding Co Ltd. CT
In other datasets, the same topic (Health) in CT:
- Nonprofit: AIDS BUDDY NETWORK (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health